Anakinra Market Report 2026

The anakinra market size has grown rapidly in recent years. It will grow from $5.46 billion in 2025 to $6.12 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to rising rheumatoid arthritis prevalence, biologics adoption growth, expansion of specialty clinics, improved diagnosis of rare diseases, increased immunology research.

The anakinra market size is expected to see rapid growth in the next few years. It will grow to $9.61 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to growth in biologic therapies, rising rare disease diagnosis, expansion of homecare settings, increasing immunology trials, growing healthcare access. Major trends in the forecast period include rising use of biologic anti-inflammatory therapies, increasing adoption in rare autoinflammatory disorders, growing focus on long-term disease control, expansion of home-based injection therapies, increased use in off-label inflammatory conditions.

The increasing prevalence of autoimmune disorders is anticipated to drive the growth of the anakinra market in the coming years. Autoimmune disorders occur when the body's immune system mistakenly attacks and damages its own healthy tissues and organs, perceiving them as harmful invaders. The rising prevalence of autoimmune disorders is attributed to genetic susceptibility and environmental influences, such as infections, pollution, and changes in diet, all contributing to the increasing occurrence of these conditions. Anakinra is utilized to manage autoimmune disorders by inhibiting interleukin-1 (IL-1) activity, thereby reducing inflammation in conditions such as rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For example, in February 2025, according to the Australian Broadcasting Corporation, a national public broadcaster in Australia, inflammatory bowel disease affects nearly 180,000 Australians, with Crohn's Disease impacting 93,700 individuals and Ulcerative Colitis affecting 80,430, and the total number is projected to reach 200,000 within the next decade. Consequently, the rising prevalence of autoimmune disorders is supporting the growth of the anakinra market.

Rising healthcare spending is anticipated to drive the growth of the anakinra market in the coming years. Healthcare spending encompasses the total funds allocated to healthcare services and products, including hospital care, physician services, medications, medical devices, and public health programs. The increase in healthcare spending is attributed to factors such as an aging population, advancements in medical technology, higher prevalence of chronic diseases, rising drug costs, greater healthcare utilization, administrative expenses, and inflation. This spending supports anakinra by financing the development, availability, and continued administration of this targeted biologic therapy, ensuring it remains an effective treatment for inflammatory conditions like rheumatoid arthritis, while also enabling its incorporation into healthcare systems through insurance coverage and patient access programs. For example, in August 2025, according to Peterson-KFF Health System Tracker, a US-based platform that provides clear, up-to-date information on trends, drivers, and issues affecting system performance, total healthcare spending in the United States is projected to reach $5.6 trillion by 2033, with hospitals accounting for the largest portion at $1.8 trillion, while overall expenditures are expected to further rise to $8.6 trillion, including $2.7 trillion for hospitals, $1.7 trillion for physician and clinic services, and $776 billion for prescription drugs. Therefore, increasing healthcare spending is fueling the growth of the anakinra market.

In March 2025, ViroGates A/S, a Denmark-based medical technology company, entered into a partnership with Swedish Orphan Biovitrum AB. The collaboration is intended to support the development and commercialization of suPARnostic in combination with Kineret (anakinra) in the US and Europe. The partnership seeks to expand suPARnostic usage across multiple diagnostic platforms while implementing a royalty payment structure for Sobi based on sales in both regions. Swedish Orphan Biovitrum AB is a Sweden-based specialized international biopharmaceutical company dedicated to transforming the lives of people with rare diseases.

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

North America was the largest region in the anakinra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anakinra market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of biologic manufacturing inputs, sterile processing materials, and cold chain logistics used in the production and distribution of anakinra. These impacts are most visible in hospital and specialty pharmacy channels, where handling requirements and supply continuity are critical. Regions such as North America and Europe have experienced higher input costs due to dependence on global biologics supply chains. Rising tariff related expenses have influenced pricing, procurement planning, and inventory management for inflammatory disease therapies. Tariffs have also encouraged localized biologics production, expanded regional manufacturing capacity, and improved long term supply resilience.

The anakinra market research report is one of a series of new reports that provides anakinra market statistics, including anakinra industry global market size, regional shares, competitors with a anakinra market share, detailed anakinra market segments, market trends and opportunities, and any further data you may need to thrive in the anakinra industry. This anakinra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anakinra is a biopharmaceutical drug that functions as a recombinant form of the human interleukin-1 receptor antagonist. It is commonly prescribed for the treatment of moderate-to-severe rheumatoid arthritis in patients who have not responded adequately to other disease-modifying antirheumatic drugs.

The primary indications for anakinra include rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial cold autoinflammatory syndrome, systemic juvenile idiopathic arthritis, adult-onset Still's disease, neonatal-onset multisystem inflammatory disease, and others. Rheumatoid arthritis is a chronic autoimmune disorder in which the immune system mistakenly targets the body’s own joint tissues, especially the synovium. It is supplied through hospital pharmacies, retail pharmacies, online pharmacies, and wholesale pharmacies, serving a range of end users, such as hospitals, clinics, and home care settings.

The Anakinra market consists of sales of diagnostic kits, supportive care products, combination therapies, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.